Русский
Studying on the progress of cardiotoxicity induced by PD-1/PD-L1 immune checkpoint inhibitors
DOI: https://dx.doi.org/10.18565/pharmateca.2024.9.155-160
Xinyi Yang, Reshetov I.V., Poltavskaya M.G., Agakina Yu.S., Kulikov T.S.
University Clinical Hospital No. 1, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Cardiotoxicity (CT) is a serious side effect of anticancer drugs, especially death receptor 1 (PD-1) or death ligand 1 (PD-L1). Immune checkpoint inhibitors (ICIs) have attracted wide attention in recent years. This article describes the progress in studying CT induced by PD-1 and PD-1/PD-L1 ICIs. An overview of PD-1 and PD-1/PD-L1 immune checkpoint inhibitors, their CT manifestations, potential mechanisms, diagnostic and therapeutic methods are presented.
About the Autors
Corresponding author: Yang Xinyi, PhD student, Department of Oncology, Reconstructive Surgery and Radiology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; xinyiyang@yandex.ru; ORCID: https://orcid.org/0009-0009-2320-0834
Similar Articles
